A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy

NCT ID: NCT04521023

Last Updated: 2020-08-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

132 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-20

Study Completion Date

2020-06-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Phase 4 clinical trial to Evaluate the blood pressure lowering effect of a Candesartan/Hydrochlorothiazide(Candemore Plus Tab) versus Candesartan/Amlodipine(Cantabell Tab) in Hypertensive Patients

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Group Type EXPERIMENTAL

Cantabell Tab

Intervention Type DRUG

Patients assigned to experimental group are treated with Cantabell Tab

B

Group Type ACTIVE_COMPARATOR

Candemore Plus Tab

Intervention Type DRUG

Patients assigned to experimental group are treated with Candemore Plus Tab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cantabell Tab

Patients assigned to experimental group are treated with Cantabell Tab

Intervention Type DRUG

Candemore Plus Tab

Patients assigned to experimental group are treated with Candemore Plus Tab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* over 19 years old
* Agreement with written informed consent
* Hypertensive Patients

Exclusion Criteria

* Patients with secondary hypertension
* Participated in other trial within 30 days
* In investigator's judgement
Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chong Kun Dang Pharmaceutical

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ajou University Hospital

Suwon, Gyeonggi-do, South Korea

Site Status

Hallym Univ. Medical Center

Anyang, , South Korea

Site Status

Daegu Catholic Univ. Medical Center

Daegu, , South Korea

Site Status

MYONGJI Hospital

Goyang-si, , South Korea

Site Status

Inje University Ilsan Paik Hospital

Ilsan-gu, , South Korea

Site Status

Gachon University Gil Medical Center

Incheon, , South Korea

Site Status

Jeju National University Hospital

Jeju City, , South Korea

Site Status

Gangnam Severance Hospital

Seoul, , South Korea

Site Status

Hallym University Kangnam Sacred Heart Hospital

Seoul, , South Korea

Site Status

Hanyang University Medical Center

Seoul, , South Korea

Site Status

Kangbuk Samsung Hospital

Seoul, , South Korea

Site Status

SNU Boramae Medical Center

Seoul, , South Korea

Site Status

Ulsan University Hospital

Ulsan, , South Korea

Site Status

Wonju Severance Christian Hospital

Wŏnju, , South Korea

Site Status

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

244HT16025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

CKD-828 (40/5mg) Pharmacokinetic Study
NCT01340131 COMPLETED PHASE1